Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
patent landscape
Start at the low end and increase gradually based on tolerance and results
Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under FFS as of January 2026 (Figure 1)
It is a synthetic compound composed of 15 amino acids derived from a protein called body protection compound found in human gastric juice
These injections are unapproved compounded products that have not been reviewed by the FDA for safety, effectiveness, or quality
Hims & Hers has a long history of controversy over compounded GLP-1s Hims & Hers began selling copycat versions of Wegovy and Ozempic in 2024, citing a regulatory loophole that allows compounding pharmacies to copy otherwise patent-protected drugs amid shortages
